SABCS 2022 | 2nd interim analysis of OS from TROPiCS-02: SG in HR+/HER2- breast cancer

Hope Rugo, MD, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, provides an overview of the second planned interim analysis of the Phase III TROPiCS-02 (NCT03901339) trial investigating sacituzumab govitecan versus treatment of physician’s choice efficacy by Trop-2 expression in patients with HR+/HER2– metastatic breast cancer (mBC) who had received previous treatment with a CDK4/6 inhibitor, at least one line of endocrine therapy and a taxane in any setting. 95% of patients had visceral metastases. The primary endpoint was progression-free survival (PFS) and key secondary endpoints were overall-survival (OS) and objective response rate (ORR). The primary analysis of TROPiCS-02 showed both a significant PFS and the second interim analysis demonstrated a significant benefit in OS. Improved efficacy was observed with sacituzumab govitecan regardless of intensity of Trop-2 expression. These results support what was observed in the Phase III ASCENT (NCT02574455) trial which explored sacituzumab govitecan in triple-negative breast cancer (TNBC), in that you do not need to test for Trop-2 to determine which patients will benefit from sacituzumab govitecan. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.